MAPS Bulletin Autumn 1990: Vol. 01, No. 3 What and Who is MAPS?

Download this entire issue or browse individual articles by title below.

 
   

 

  What and Who is MAPS? Rick Doblin, Ph.D.
  The Two Functions of MAPS Rick Doblin, Ph.D.
  Thoughts About the Ethics of Animal Research Rick Doblin, Ph.D.
  MDMA Neurotoxicity Overview Rick Doblin, Ph.D.
  Preliminary Findings from Primate Neurotoxicity Studies Rick Doblin, Ph.D.
  Dr. Nichols Confirms that Prozac Blocks MDMA Neurotoxicity Rick Doblin, Ph.D.
  Requested – Subjective Reports of the Prozac / MDMA Combinations Rick Doblin, Ph.D.
  Findings From the Two NIDA-Funded MDMA Human Studies Rick Doblin, Ph.D.
  A Call for Volunteers for the Johns Hopkins MDMA Human Neurotoxicity Study

Rick Doblin, Ph.D.
  Update on Swiss Psychedelic Research

Rick Doblin, Ph.D.
  Unsuccessful MAPS Attempts at Collaborative Research

Rick Doblin, Ph.D.
  Swiss Psychedelic Usage Halted – Resumption Possible But Not Certain

Rick Doblin, Ph.D.
  New Opportunities for MDMA Research in Czechoslovakia

Rick Doblin, Ph.D.
  The MAPS International Research Methodology Conference

Rick Doblin, Ph.D.
  Pharmaceutical Companies Study the Market For Psychedelics

Rick Doblin, Ph.D.
  MAPS’ Research Agenda and Financial Requests

Rick Doblin, Ph.D.